Preclinical Evaluation of 5T4-Targeted [ <sup>89</sup> Zr]Zr-DFO-HB5 Immuno-PET Imaging and Comparison of <sup>161</sup> Tb vs <sup>177</sup> Lu Radionuclide Therapy for Colorectal Cancer
Yuanyuan LiangUniversity of Electronic Science and Technology of ChinaXiangyun LiState Key Laboratory of Biotherapy, Department of Biotherapy, West China HospitalHui LiangUniversity of Electronic Science and Technology of ChinaTao WuUniversity of Electronic Science and Technology of ChinaYao HuangNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of MedicineShoumei LiuNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of MedicineXia YangChina Academy of Engineering PhysicsRui LuoUniversity of Electronic Science and Technology of ChinaFanxin MaSound Biopharmaceuticals Co., Ltd., Tianfu International Bio-Town, Huigu Dong Second Road 8, Chengdu, Sichuan 610200, ChinaYing HuangSound Biopharmaceuticals Co., Ltd., Tianfu International Bio-Town, Huigu Dong Second Road 8, Chengdu, Sichuan 610200, ChinaXiaoan LiNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of MedicineYan ZhouUniversity of Electronic Science and Technology of China
ABI
Annotatsiya
Tb]Tb-DOTA-HB5 exhibits potent antitumor efficacy and favorable biosafety. The study provides a potential theranostic platform for 5T4-positive CRC and related malignancies.
Hali tarjima qilinmagan
Mavzular
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos49 ta foydalanilgan manba